TRML: שווי חברה לרווח נקי Tourmaline Bio Inc

Tourmaline Bio, Inc. (TRML) collaborates with scientific centers to develop therapies for rare immune pathologies. Strong patent protection for antibodies in untapped niches guarantees high profitability. However, success depends on a single asset and the availability of capital. The P/E ratio trend helps assess the company's market value, where -14.10 shows the current value of the metric.
פילוחים אנליטיים של חברת Tourmaline Corp (TRML)

Tourmaline Bio, Inc. (TRML) specialization in unique therapies for immune pathologies drives a high business valuation premium, which is reflected in the ratio of market capitalization to net income. This coefficient measures the investment payback period, allowing for an assessment of the current balance between market expectations and actual financial results via the company's average P/E.